Cutis
-
Clinical Trial
Antipruritic hydrogel for the treatment of atopic dermatitis: an open-label pilot study.
Atopic dermatitis (AD) is the most common chronic inflammatory skin disease in industrialized nations. The efficacy and tolerability of Atrapro (RD047-26) antipruritic hydrogel was evaluated in 17 adult participants with mild to moderate AD with associated pruritus. The antipruritic hydrogel was applied 3 times daily to the affected areas of the body, and participants were evaluated on days 3, 7, and 14 (end of study). ⋯ Most participants (82% [14/17]) experienced relief from itching by day 3, and this improvement remained consistent at each of the follow-up office visits. The only adverse event (AE) was mild postapplication skin dryness, which was reported by 59% (10/17) of participants and resolved with increased use of emollients. Based on these promising results, further research on the antipruritic hydrogel is warranted.
-
Case Reports
Acneiform eruptions induced by epidermal growth factor receptor inhibitors: treatment with oral isotretinoin.
The most common cutaneous side effects to epidermal growth factor receptor (EGFR) inhibitors are follicular or acneiform eruptions, nail disorders, xerosis, and desquamation. Although topical and oral antibiotics with or without topical corticosteroids usually are safe and effective treatment options for acneiform eruptions due to EGFR inhibitors, they are not always successful in refractory cases. ⋯ Complete response was observed in all 3 patients. We recommend oral isotretinoin for the management of acneiform reactions to EGFR inhibitors when the lesions persist or worsen despite antibiotic treatment.